Startups
R-Pharm JSC acquires rights to Tarsa’s TBRIA™, novel oral treatment for post-menopausal osteoporosis Tarsa Therapeutics developed TBRIA™, a novel oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable. This product has the potential to be the
Overview
Location
United States, Pennsylvania, Philadelphia
Employees
11-50
Total raised
$45M
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 29, 2014 | Series B round | $7M | |
| Mar 16, 2012 | Series B round | $28M |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 13, 2014 | Tarsa Therapeutics Secures $10M Senior Credit Facility | Tarsa Therapeutics, Inc., a Philadelphia, PA-based developer of a formulation of calcitonin for the treatment of postmenopausal osteoporosis, secured a $10m senior credit facility. Oxford Finance LLC and Square 1 Bank provided the financing... |
| May 29, 2014 | Tarsa Therapeutics Raises $7M in Second Tranche of Series B Round | Tarsa Therapeutics, Inc., a Philadelphia, PA-based developer of oral calcitonin for the treatment and prevention of osteoporosis, raised $7m in the second tranche of a Series B round. Backers included existing investors Foresite Capital, MV... |
| Mar 16, 2012 | Tarsa Therapeutics Closes $28M Series B Equity Financing | Tarsa Therapeutics, Inc., a Philadelphia, PA-based developer of a novel oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis, has closed a $28m Series B equity financing. The round was led by new in... |
| Mar 16, 2012 | Tarsa Therapeutics Completes $28M Series B | PHILADELPHIA, PA, Series B equity financing led by new investor Foresite Capital. Tarsa's existing venture capital investors, Novo A/S, MVM Life Science Partners and Quaker Partners, all participated in the new financing round. >> ... |
| Mar 16, 2012 | Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing | The drug is a peptide hormone that would be destroyed by the digestive system if taken orally, but the technology behind the drug is intended to prevent that from happening. The technology is licensed from Unigene. Under the terms of the ag... |
| Oct 21, 2009 | Tarsa Therapeutics Raises $24M | Newly formed Tarsa Therapeutics, Inc. announced the closing of a $24m Series A financing from a syndicate of three venture capital funds specializing in the life sciences including MVM Life Science Partners, Quaker BioVentures and Novo A/S.... |
| Tarsa Therapeutics raises capital for osteoporosis drug that’s in NDA screening | Philadelphia-based Tarsa Therapeutics, which is developing an oral form of the peptide hormone called salmon calcitonin that helps prevent osteoporosis. The company just raised $2 million, according to a regulatory filing. This is its first... | |
| Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing | A therapeutics company has raised $28 million in a series B financing round in the run-up to submitting its new drug application later this year for its oral calcitonin remedy to treat and cure osteoporosis in postmenopausal women. Tarsa Th... |
Reviews 0
FAQ about Tarsa Therapeutics, Inc
How much funding has Tarsa Therapeutics, Inc raised?
Tarsa Therapeutics, Inc has raised $45M in total across 3 funding rounds.
What funding rounds has Tarsa Therapeutics, Inc raised?
Parsers VC lists 3 funding rounds of Tarsa Therapeutics, Inc, among them a Series B round of $7M on May 29, 2014 and a Series B round of $28M on Mar 16, 2012.
What has the press written about Tarsa Therapeutics, Inc?
Parsers VC has collected 9 articles mentioning Tarsa Therapeutics, Inc, among them “Tarsa Therapeutics Secures $10M Senior Credit Facility” (Aug 13, 2014) and “Tarsa Therapeutics Raises $7M in Second Tranche of Series B Round” (May 29, 2014).
Is Tarsa Therapeutics, Inc still active?
Yes, Tarsa Therapeutics, Inc is active; its latest activity on Parsers VC dates from Feb 19, 2016.